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Thrombospondin-1 (TSP-1) is a large matricellular glycoprotein known to be
overexpressed within tumor stroma in several cancer types. While mainly considered
as an endogenous angiogenesis inhibitor, TSP-1 exhibits multifaceted functionalities
in a tumor context depending both on TSP-1 concentration as well as differential
receptor expression by cancer cells and on tumor-associated stromal cells. Besides, the
complex modular structure of TSP-1 along with the wide variety of its soluble ligands and
membrane receptors considerably increases the complexity of therapeutically targeting
interactions involving TSP-1 ligation of cell-surface receptors. Despite the pleiotropic
nature of TSP-1, many different antireceptor strategies have been developed giving
promising results in preclinical models. However, transition to clinical trials often led to
nuanced outcomes mainly due to frequent severe adverse effects. In this review, we will
first expose the intricate and even sometimes opposite effects of TSP-1-related signaling
on tumor progression by paying particular attention to modulation of angiogenesis
and tumor immunity. Then, we will provide an overview of current developments and
prospects by focusing particularly on the cell-surface molecules CD47 and CD36 that
function as TSP-1 receptors; including antibody-based approaches, therapeutic gene
modulation and the use of peptidomimetics. Finally, we will discuss original approaches
specifically targeting TSP-1 domains, as well as innovative combination strategies with
a view to producing an overall anticancer response.
Keywords: TSP-1, CD47, CD46, cancer, angiogenesis, innovative therapeutic strategies
STATE OF THE ART
In view of the relatively short-lived beneﬁts observed in targeted therapies that aim at facing
advanced primary cancers, the current main therapeutic challenge is to identify original molecular
targets in order to limit tumor burden without allowing resistance acquisition (van Beijnum et al.,
2015). Indeed, the advent of systems biology over recent years underlined the limits of therapeutic
agents designed to block a single pathway and/or growth factor, inevitably leading to the activation
of compensatory mechanisms which allow tumor escape and restore disease progression (Wilson
et al., 2015). To face the complexity and massive redundancy of signaling pathways and regulatory
Abbreviations: 3TSR, three thrombospondin-1 type 1 repeats; ECM, extracellular matrix; EOC, epithelial ovarian cancer;
FGF-2, ﬁbroblast growth factor-2; MET, metronomic; MTD, maximum tolerated dose; PD, pharmacodynamic; PK,
pharmacokinetic; RBCs, red blood cells; SIRPα, signal regulatory protein alpha; TCR, T cell receptor; TRAIL, tumor necrosis
factor-related apoptosis-inducing ligand; TSP-1, thrombospondin-1; VEGFR2, vascular endothelial growth factor receptor 2.
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processes underlying tumor progression, growing attention is
accorded to matricellular proteins and their cell receptors as
they function as multiple integrators of tumor progression
signals at the tumor/microenvironment interface (Murphy-
Ullrich and Sage, 2014). According to their deﬁnition ﬁrst given
by Paul Bornstein 25 years ago, matricellular proteins regulate
a wide range of both malignant and stromal cell functions
through interactions with cell-surface receptors or by acting in
a coordinated manner with other ECM components or soluble
molecules (Sage and Bornstein, 1991). TSPs may be regarded as
the archetypes of the matricellular protein group, with TSP-1 ﬁrst
identiﬁed from human platelets in 1978 (Lawler et al., 1978).
Thrombospondin-1 is considered a main actor within
a tumor microenvironment, while it exerts intricate and
sometimes opposite eﬀects on tumor progression. Elevated
circulating levels of TSP-1 were early observed in patients
presenting breast, lung, gastrointestinal or even gynecological
malignancies (Tuszynski et al., 1992; Nathan et al., 1994). In
patients receiving myelosuppressive anti-cancer chemotherapy,
TSP-1 blood concentrations assessments strongly correspond
with platelet counts (Starlinger et al., 2010). Of note, such
correlation is also observed in non-malignant processes where
platelet activation is high, such as sickle cell disease (Novelli
et al., 2012). Nevertheless, others have noted that elevation of
circulating TSP-1 in a cancer setting could be even noticed
in absence of plasma contamination by platelet activation
(Byrne et al., 2007), thus suggesting that TSP-1 plasma levels
might originate from sources other than platelets. Therefore,
additional work is needed to determine the exact origins
of high TSP-1 plasma concentrations, particularly as many
non-platelet sources are known to produce TSP-1 such as
endothelial cells, cancer cells, or even circulating immune
cells (Dawes et al., 1988). Among the range of possibilities,
tumor-originating TSP-1 may provide a plausible explanation
to elevated levels detected in patients. Indeed, increased TSP-1
mRNA and/or protein levels were observed within the stromal
compartment of breast and gastric carcinoma (Clezardin et al.,
1993; Brown et al., 1999; Lin et al., 2012). On the contrary,
carcinoma cells express undetectable to low levels of TSP-
1 in these studies, and loss of TSP-1 expression by cancer
cells is described as an important feature of the “angiogenic
switch” in a wide range of solid tumors (Naumov et al.,
2006). Indeed, TSP-1 expression is typically down-regulated
by oncogenes whereas it is promoted by tumor suppressor
genes such as p53 (Dameron et al., 1994). Recently, oncogenic
Ras was conﬁrmed as being likely to induce phosphorylation
of Myc, thus leading to TSP-1 repression and acquisition
of an angiogenic phenotype (Watnick et al., 2015). While
TSP-1 expression is lost during malignant progression in a
wide variety of major cancer types, a few exceptions need
nevertheless to be considered. By way of example, TSP-1 is
over-expressed by invasive and metastatic melanoma cells, in
which it actively contributes to an epithelial-to-mesenchymal
transition program (Jayachandran et al., 2014; Borsotti et al.,
2015).
Like other matricellular proteins, TSP-1 is a multi-modular
and multifunctional protein able to bind a wide variety of ligands,
thus considerably increasing the complexity of its translational
potential. As a consequence, it seems obvious that strategies
blindly targeting a speciﬁc function such as gross matricellular
protein silencing, or the use of blocking antibodies, may induce
severe adverse eﬀects. Indeed the beneﬁcial properties of the
multifunctional protein may also be lost under such treatment.
Here, we will focus on TSP-1 and two of its receptors viz. CD47
and CD36, to review pre-clinical and clinical outcomes that could
be achieved with current developments. Then, we will discuss
future directions to target these cell-surface receptors, using small
molecules and peptides able to interfere with TSP-1/CD47 as
well as TSP-1/CD36 signaling axis in order to reach an overall
anticancer response.
TSP-1: A MAIN ACTOR WITHIN TUMOR
MICROENVIRONMENT
Thrombospondin-1 has long been considered to play a role
in tumor progression; several studies carried out 20 years ago
found it to be overexpressed within tumor stroma and in high
circulating levels in several cancers (Qian and Tuszynski, 1996;
Bertin et al., 1997; Brown et al., 1999). TSP-1 was also reported
to contribute to metastatic spread by promoting tumor cell
emboli formation (Incardona et al., 1995). In recent years, an
increasing number of studies have tended to present TSP-1 as
a poor prognosis and recurrence marker in many cancer types
including glioma (Perez-Janices et al., 2015), melanoma (Borsotti
et al., 2015) as well as ovarian and pancreatic carcinomas (Lyu
et al., 2013; Nie et al., 2014; Pinessi et al., 2015). Among
TSP-1 ligands, CD36 and CD47 cell-surface receptors act as
key integrators of multiple signals regulating tumor growth
and dissemination both positively and negatively. Indeed, TSP-
1/CD36/CD47 trimolecular signaling platform dynamics as
well as interactions involving co-receptors and soluble ligands
exert pleiotropic activities on cancer progression, by directly
modulating cancer cells behavior or by acting on tumor
microenvironment stromal cells (Kazerounian et al., 2008; Sick
et al., 2012).
Modulation of Angiogenesis by TSP-1
Thrombospondin-1 is widely known as an endogenous inhibitor
of angiogenesis by negatively regulating NO-mediated signaling
in endothelial cells, vSMC and platelets (Isenberg et al.,
2008a, 2009b). TSP-1 inhibition of NO/cGMP-related pathways
and subsequent antiangiogenic activities are mediated by its
interaction with two cell-surface receptors: CD47 and CD36
(Isenberg et al., 2009c; Zhang et al., 2009). CD47 is a
ubiquitous 50 kDa receptor consisting of a single N-terminal
IgV extracellular domain, ﬁve membrane-spanning segments
and a short C-terminal cytoplasmic tail (Sick et al., 2012).
Although it is now commonly referred to by its immunological
marker name, CD47 receptor was ﬁrst identiﬁed through its
association with αVβ3 integrin, therefore justifying its former
name IAP (integrin associated protein; Brown et al., 1990). At
the same time, the ovarian tumor antigen OA3 was characterized
(Campbell et al., 1992) and subsequently shown to be the
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same protein as CD47 (Mawby et al., 1994). CD47 is widely
considered as a marker of “self,” and is therefore highly expressed
by circulating hematopoietic stem cells, erythrocytes and many
malignant cells (Oldenborg et al., 2000; Jaiswal et al., 2009).
Notably, CD47 was described as a marker of tumor-initiating
cells in leukemia as well as in bladder and liver cancer (Chan
et al., 2009; Willingham et al., 2012a; Lee et al., 2014). In
cancer, CD47 acts as a “don’t eat me” signal by engaging
its macrophage phagocytic counter-receptor SIRPα (signal
regulatory protein alpha; Vernon-Wilson et al., 2000; Chao et al.,
2012). Thus, CD47 binding to SIRPα present on immune cells
causes a dephosphorylation cascade avoiding synaptic myosin
accumulation and thereby preventing engulfment (Tsai and
Discher, 2008). However, broad evidence now sustains that CD47
signaling functions go well beyond this simple antiphagocytic
passive role, with CD47 acting as a sensor for cell–cell and
cell–microenvironment signals. Indeed SIRPα can interact with
CD47 receptors in cis or in trans, and CD47/SIRPα signaling
should not be considered as unidirectional in so far as SIRPα
binding can in turn aﬀect intracellular signaling through CD47
(Latour et al., 2001), which has further been called “reverse”
signaling (Sarfati et al., 2008). While this provides an exciting
area for future research, numerous studies of CD47 signaling
functions that have been published so far focused on CD47
activation by TSP-1. Indeed, TSP-1 available within the ECM
is a key regulator of CD47 signaling. CD47 ligation by TSP-
1 C-terminal domain dissociates its constitutive association
with VEGFR2 and allows inhibition of both early eNOS-
activating signals and NO-independent VEGFR2 signaling, thus
leading to subsequent antiangiogenic responses (Kaur et al.,
2010; Soto-Pantoja et al., 2015). Remarkably, TSP-1:CD47
interaction also redundantly inhibits NO signaling at the level
of such downstream eﬀectors as soluble guanylate cyclases (sGC;
Isenberg et al., 2006) and cGMP-dependent protein kinases
(cGK; Isenberg et al., 2008a,c). Of note, co-immunoprecipitations
experiments were recently conducted identifying for the ﬁrst
time TSP-1 as a new ligand for SIRPα, which may result in
stimulation of SIRPα phosphorylation and downstream signaling
in non-phagocytic cells (Yao et al., 2014). While this process
is likely to involve the joint contribution of CD47, it raises
the exciting likelihood of a CD47-independent SIRPα signaling
under TSP-1 ligation. As cell-free binding assays indicated
that TSP-1:SIRPα interaction does not imply the C-terminal
domain of TSP-1, further studies considering recombinant
fragments as well as molecular docking experiments would
be of particular interest to better characterize this newly
identiﬁed interaction. To further increase the complexity of
TSP-1/CD47/SIRPα signaling axis, it has to be noted that both
CD47 and SIRPα ectodomains could be target of sheddases
and thus provide additional ligands for TSP-1, CD47, and
SIRPα (Ohnishi et al., 2004; Maile et al., 2008; Toth et al.,
2013).
In addition to CD47-induced eﬀects, a central region of
TSP-1 called 3TSR (three TSP-1 type 1 repeats) binds itself
to the CD36 membrane receptor, also leading to angiogenesis
inhibition. CD36, ﬁrst identiﬁed from platelets as glycoprotein
IV (GpIV; Clemetson et al., 1977), is a class B scavenger
receptor (Calvo et al., 1995) also acting as fatty acid translocase
(Pohl et al., 2005). It is mostly expressed by microvascular
endothelial cells and vSMC (Dawson et al., 1997; Silverstein
and Febbraio, 2009) in which TSP-1 ligation promotes CD36
association with β1 integrin and VEGFR2 dimer in a tripartite
complex, resulting in decreased VEGFR2 phosphorylation under
VEGF stimulation (Zhang et al., 2009). Besides, TSP-1 binding
to CD36 inhibits NO-related signaling at the level of eNOS by
preventing myristate uptake and also its downstream eﬀects.
Indeed, both TSP-1 and a peptide derived from the 3TSR as well
as a CD36 “agonist” mAb are able to modulate the fatty acid
translocase activity of CD36 by preventing myristate uptake in
vascular cells (Isenberg et al., 2007). As CD36 is expected to be
the main cell membrane protein involved in fatty acid uptake
(Koonen et al., 2005), one should bear in mind that targeting
this receptor may aﬀect lipoprotein and glucose metabolism,
and therefore lead to cardiovascular complications. In humans,
CD36 deﬁciency is associated with phenotypic expression of the
“metabolic syndrome,” i.e., hypercholesterolemia, hyperglycemia,
insulin resistance, and higher blood pressure (Hirano et al.,
2003). Besides, TSP-1 and TSP-1-derived agents that inhibit
myristate uptake through CD36 activation are also likely to aﬀect
non angiogenesis-related signaling pathways as post-translational
myristoylation regulates many protein and cell functions (Martin
et al., 2011). While TSP-1 is a high aﬃnity ligand for CD47,
binding to CD36 requires higher concentrations that overcome
physiological levels. Apart from this 100-fold diﬀerence in
binding aﬃnities, results from null cells and animals also indicate
that while TSP-1 ligation of either CD36 or CD47 is suﬃcient
to inhibit NO-stimulated vascular responses, only CD47 is
necessary for such TSP-1 activity at physiological concentrations
(Isenberg et al., 2006). However, considering that TSP-1 protein
levels in tumor and surrounding tissue are found to be elevated in
several cancers (for review, see Kazerounian et al., 2008), one can
assume that CD36-activating concentrations are reached within a
tumor microenvironment.
TSP-1 Direct Impact on Cancer Cell
Behavior and Tumor Immunity
Far from being restricted to angiogenesis modulation, the
eﬀects of TSP-1 on tumor progression are multifaceted and
sometimes even opposite depending on the molecular and
cellular composition of the microenvironment. Indeed, its ability
to interact with multiple ligands enables TSP-1 to regulate a wide
range of processes such as tumor cell adhesion (Li et al., 2006),
proliferation (Sick et al., 2011), survival or apoptosis (Manna
and Frazier, 2004; Saumet et al., 2005; Rath et al., 2006a,b),
tumor invasion and metastatic dissemination (Jayachandran
et al., 2014; Borsotti et al., 2015), inﬂammation, immune
response (Grimbert et al., 2006) and response to treatment
(Lih et al., 2006; Bi et al., 2014). Such pleiotropic eﬀects
may be governed by TSP-1 concentration as well as by its
origin, whether it originates from tumor cells or the stroma
compartment (Pinessi et al., 2015). Reverse responses may also
be observed depending on the cancer type. For instance, CD47
ligation by TSP-1 induces killing of breast cancer cells (Manna
and Frazier, 2004) while it was reported to inhibit apoptosis
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and promote drug resistance in thyroid carcinoma cells (Rath
et al., 2006a,b). Besides, TSP-1 can also trigger cancer cell death
by interacting with the CD36 receptor as recombinant 3TSR
fragments of TSP-1 were shown to inhibit proliferation and
to induce apoptosis of murine epithelial ovarian cancer cells
(EOC; Russell et al., 2015). Therefore, TSP-1 eﬀects on malignant
cells are dependent on receptor expression proﬁles that are
likely to vary between diﬀerent malignant subpopulations or
even depending on their diﬀerentiation degrees (Zheng et al.,
2015).
Apart from TSP-1-related direct modulation of cancer cell
behavior through interactions with membrane receptors, the
TSP-1/CD47/SIRPα axis is also strongly implicated in controlling
tumor immunity, with both positive and negative roles. A widely
held opinion is that tumor cells express high CD47 levels
to inhibit phagocytosis by signaling through SIRPα found
on macrophages and dendritic cells (DCs; Zhao et al., 2011;
Chao et al., 2012; Willingham et al., 2012a). Accordingly,
restoration of CD47 expression in CD47-deﬁcient leukemia
cells increases xenograft aggressiveness (Jaiswal et al., 2009).
To date, CD47/SIRPα is the only known negative regulator
of phagocytosis at the immunological synapse and it is
known to play an important physiological role in maintaining
hematopoietic cells and platelets homeostasis (Olsson et al., 2005;
Sick et al., 2012). In addition, CD47:SIRPα interaction may
also indirectly promote tumor dissemination through binding
of tumor cells to macrophages that reside at the level of
potential extravasation sites within the vascular wall (Chao et al.,
2011b). Several structural and mutagenesis studies highlighted
that according to their respective spatial conﬁguration within
CD47 extracellular domain, the TSP-1 and SIRPα interaction
sites may not be redundant (Floquet et al., 2008; Hatherley
et al., 2008; Jeanne et al., 2015; Soto-Pantoja et al., 2015).
However, direct binding assays provided contradictory evidence
as both TSP-1 and a function-blocking CD47 antibody inhibit
CD47:SIRPα interaction (Isenberg et al., 2009a). Furthermore,
recent studies underlined that TSP-1 may also interact with
SIRPα (Yao et al., 2014), thus accentuating the impression that
the above-mentioned studies asserting an essential contribution
of the CD47:SIRPα “don’t eat me” signal remains incomplete,
especially as none of this work was done controlling the absence
or presence of TSP-1.
Aside from the previously exposed modulation of innate
immunity by the CD47/SIRPα antiphagocytic axis, TSP-
1 interaction with CD47 existing on immune cells mostly
inactivates antitumor adaptive immunosurveillance. Indeed TSP-
1 was shown to directly inhibit TCR-mediated T cell activation
(Li et al., 2001) by engaging CD47 (Li et al., 2002). Secreted
TSP-1 that binds CD47 on T cells inhibits both the NO/cGMP
pathway (Ramanathan et al., 2011) and H2S signaling (Kaur
et al., 2015), therefore concomitantly resulting in an homeostatic
inhibitory role of TSP-1:CD47 interaction on T-cell activation.
On the other hand, there are cross-talks between the above
described mechanisms and VEGF signaling in T cells. Thus,
CD47 ligation by TSP-1 inhibits VEGFR2 phosphorylation hence
limiting VEGF-induced inhibition of T cell proliferation and
TCR signaling (Kaur et al., 2014). Otherwise, TSP-1 binding
to CD47 also inhibits diﬀerentiation of naïve T cells into
Th1 (Bouguermouh et al., 2008), whereas Tregs formation is
induced by promoting Foxp3 transcription factor expression
(Grimbert et al., 2006; Baumgartner et al., 2008). In cancer,
CD47 blockade was shown to enhance antitumor immunity by
stimulating CD8+ cytotoxic T cells (Soto-Pantoja et al., 2014).
In combination with ionizing radiotherapy that enhances T
cell antitumor immunity (Demaria and Formenti, 2012), CD47
blockade in eﬀector T cells is therefore suﬃcient to inhibit
tumor growth, thus oﬀsetting the widely spread opinion that
CD47 blockade anticancer eﬀects are attributed to phagocytosis
of cancer cells by macrophages. CD47 signaling also regulates
natural killer (NK) and DC functions that orchestrate adaptative
immunity, leading to tolerogenic signals toward tumor under
TSP-1 ligation (Kim et al., 2008; Weng et al., 2014).
Considering these contradictory data, one should realize that
TSP-1 roles in cancer progression and metastatic dissemination
are complicated and intricate, often leading to paradoxical
signals. Indeed, for the purpose of designing new therapeutics,
one should bear in mind that several ECM soluble factors
and/or cell-surface receptors could bind simultaneously and
act as competitors, or even allosterically inﬂuence each other’s
binding and signaling. Therefore, it seems obvious that TSP-
1 and/or its receptors massive blockade or silencing may lead
to inevitable adverse eﬀects, closely related to the pleiotropic
nature of matricellular proteins and their ligands. Despite these
considerations, a few strategies have shown promising results in
animal cancer models and some of them alreadymoved to clinical
trials.
THERAPEUTIC TARGETING OF
TSP-1-RELATED SIGNALING
Therapeutic strategies targeting TSP-1 signaling and its
CD47/CD36 membrane receptors have already been extensively
reviewed over the last 5 years (Belotti et al., 2011; Henkin and
Volpert, 2011; Sick et al., 2012; Soto-Pantoja et al., 2013b).
Thereby, this review is not meant as a comprehensive overview,
but rather as a snapshot of current pre-clinical to clinical
developments. The range of new therapeutic methods support
the sharply expanding interest in targeting TSP-1-related
signaling with a view to regulating its function during cancer
progression. After describing the most advanced strategies
(summarized in Table 1) as well as their beneﬁts and limitations,
we will discuss more original and sophisticated approaches
which aim at modulating TSP-1/CD47/CD36 signalization either
directly or indirectly in order to provide an overall anticancer
response. Then we will consider future directions and treatment
optimizations with the objective of improving further clinical
outcomes.
Antibody Blockade and Gene
Therapeutics
The use of monoclonal antibodies (mAbs) is an obvious way to
therapeutical target cell-surface receptors. Considerable eﬀorts
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TABLE 1 | Therapeutic strategies targeting TSP-1-related signaling.
Compound Origin/sequence Target Stage Reference
CD47-blocking
mAb
CD47 Phase 1 clinicaltrials.gov (four trial studies
ongoing)
CD47 antisense
morpholino
CD47 Pre-clinic Maxhimer et al., 2009
Peptides
4N1/4N1-K TSP-1 (K-RFYVVMWK-K) CD47 Pre-clinic Kalas et al., 2013
7N3 TSP-1 (FIRVVMYEGKK) CD47 In vitro Maxhimer et al., 2009
PKHB1 i.e., 4N1K, with D counterparts
for N- and C-terminal lysines
CD47 Pre-clinic Martinez-Torres et al., 2015
TAX2 CD47 (CEVSQLLKGDAC) TSP-1 Pre-clinic Jeanne et al., 2015
Psap-derived
peptide
Prosaposin (DWLPK) TSP-1
upregulation in
Gr1+ cells
Pre-clinic Catena et al., 2013
TSP-1
recombinant
fragment
TSP-1
3TSR Type 1 repeats CD36 Pre-clinic Zhang et al., 2005
3TSR/TRAIL fusion
protein
Type 1 repeats, TRAIL CD36 and
TRAIL receptor
Pre-clinic Choi et al., 2015
Peptidomimetics
ABT-526 (Abbott) TSP-1 type 1 repeats (GVITRIR) CD36 Pre-clinic Rusk et al., 2006
ABT-510 (Abbott) TSP-1 type 1 repeats (GVITRIR) CD36 Phase 2 Baker et al., 2008
ABT-898 (Abbott) TSP-1 type 1 repeats (GVITRIR) CD36 Pre-clinic Campbell et al., 2011
CVX-022 (Pfizer) TSP-1 mimetic + scaffold Ab CD36 Pre-clinic Coronella et al., 2009
CVX-045 (Pfizer) TSP-1 mimetic + scaffold Ab CD36 Phase 1 Molckovsky and Siu, 2008
Non-peptide small molecule
sm27 TSP-1 type 3 repeats FGF-2 Pre-clinic Taraboletti et al., 2010
Others
Trabectedin
(ET-743, Yondelis)
Marine natural product TSP-1
upregulation by
tumor cells
Approved Monk et al., 2012; Dossi et al., 2015
Velcro-CD47
(N3612)
CD47 extracellular domain SIRPα In vitro Ho et al., 2015
have focused on developing CD47-targeting mAbs to block
the CD47/SIRPα antiphagocytic pathway established between
tumor cells and immune cells. Such CD47-blocking mAbs were
shown to be eﬀective by allowing the decrease of tumor burden
in several preclinical cancer models including acute myeloid
leukemia (Majeti et al., 2009), lymphoma (Chao et al., 2010)
and osteosarcoma (Xu et al., 2015). While the decrease in tumor
growth is mainly attributed to enhanced tumor cell clearance by
macrophages under CD47:SIRPα disruption (Willingham et al.,
2012a), other studies have noted that alternativemechanismsmay
explain the antitumor activities of CD47-blocking antibodies.
Particularly, the use of intact IgG (such as B6H12 anti-CD47
Ab) in the previously mentioned in vivo experiments may also
induce Fc-mediated cytotoxicity (Zhao et al., 2011). Of note,
one of the CD47-blocking antibody that reduced tumor growth
(clone miap410; Willingham et al., 2012b) raised doubts as to
its ability to block CD47:SIRPα interaction (Han et al., 2000;
Willingham et al., 2012b). Altogether, these data suggest that
increased macrophage phagocytosis is not suﬃcient to explain
antitumor activities of CD47-targeting mAbs and that other
actors are involved (Soto-Pantoja et al., 2012a; Zhao et al.,
2012). Particularly, in vitro and in vivo studies have shown that
macrophages are able to prime an eﬀective CD8+ T cell response
following anti-CD47 treatment-mediated phagocytosis of cancer
cells, by concomitantly inducing a reduction in regulatory T cell
population (Tseng et al., 2013). To date, at least four ﬁrst-in-
man phase 1 clinical trials considering anti-CD47 humanized
mAbs are underway, according to clinicaltrials.gov website
(identiﬁers NCT02216409, NCT02447354, NCT02488811, and
NCT02367196). Given the ubiquitous expression of CD47,
systemically administered anti-CD47 mAbs will inevitably come
across a huge number of CD47 copies on red blood cells
(RBCs). To avoid phagocytic-induced excessive reduction in
erythrocytes count, it has been suggested to use a priming-
dose of anti-CD47 that would result in “aged” RBCs removal
and subsequent erythropoiesis stimulation (McCracken et al.,
2015). Such suggestion is obviously questionable, as many
other clearance mechanisms are known to be preponderant in
triggering removal of senescent RBCs (Lutz and Bogdanova,
2013). One should note that experiments considering CD47
targeting agents in mice did not induce any signiﬁcant anemia,
which also runs counter to a major role for antiphagocytic
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“don’t eat me” signal disruption in these studies. Besides,
CD47 plays fundamental physiological roles by limiting NO
signaling in RBCs, platelets, and endothelium (Soto-Pantoja
et al., 2015). Indeed, CD47 antibody targeting may aﬀect NO
pathway modulation and subsequent angiogenesis regulation,
since a commonly used CD47-blocking antibody (clone B6H12)
was previously shown to concomitantly disrupt both TSP-
1:CD47 and CD47:SIRPα interactions (Isenberg et al., 2009a).
As pre-clinical data suggests that high circulating TSP-1 levels
produced by tumor stroma may indirectly increase tumor
perfusion while decreasing peritumoral and systemic blood
ﬂow, CD47-targeting mAbs are therefore likely to counteract
these eﬀects through regional stimulation of NO signaling
(Isenberg et al., 2008b, 2009b). On the other hand, anti-CD47
antibodies may also interfere with CD36-mediated modulation
of NO signaling, as CD47 is required for CD36 activation
under TSP-1 ligation (Isenberg et al., 2006). According to
this, systemic administrations of anti-CD47 mAbs for cancer
treatment would probably lead to severe adverse events such
as hypertension and thrombosis. Therefore, we are not fully
persuaded by the use of CD47 antibodies as an alternative
to current anticancer drugs, while their local use is much
more promising for instance in ischemia prevention (Lin et al.,
2014).
As RBCs have prolonged circulating lifetimes without any
membrane protein turnover (Mohandas and Gallagher, 2008),
other groups have suggested that acute genetic modulation of
CD47 expression may represent a surrogate to some of the
antibody-based strategies side-eﬀects. Indeed CD47 antisense
morpholino potently reduced tumor burden in patient-derived
hepatocellular carcinoma xenografts (Lee et al., 2014). This study
highlighted that the use of morpholino against CD47 mRNA
may be of particular interest in combination with conventional
chemotherapy as it potentialized the eﬀects of doxorubicin.
In the context of syngeneic melanoma allografts, morpholino
suppression of CD47 expression induced only a modest decrease
of tumor growth (Maxhimer et al., 2009). There again, more
beneﬁcial eﬀects were reached when combining morpholino
treatment with radiotherapy in the same allograft model. It
should be noted that similar inhibition of tumor growth is
observed when irradiating TSP-1 null mice, thus suggesting that
anticancer targeting of TSP-1:CD47 interaction would be of a
greater relevance than disrupting CD47:SIRPα (Isenberg et al.,
2008c; Soto-Pantoja et al., 2013b). Accordingly, TSP-1 silencing
in DCs by shRNA interference exhibited antitumor eﬀects in a
bladder cancer syngeneic model, by increasing tumor-inﬁltrating
CD4+ and CD8+ T cells (Weng et al., 2014). There again, TSP-
1 wide-spread silencing may be a double-edged sword for cancer
therapy as TSP-1 exerts opposite eﬀects in endothelial cells and
DCs. Therefore, the use of TSP-1 recombinant fragments or small
antagonistic molecules may be of a better interest.
TSP-1-derived Peptides, Recombinant
Fragments, and Mimetics
Several synthetic peptides derived from the C-terminal domain
of TSP-1 were early identiﬁed as containing a critical VVM
motif proposed to be essential for CD47 binding (Gao
and Frazier, 1994). Among them, the widely used 4N1
(1016RFYVVMWK1024) and 7N3 (1102FIRVVMYEGKK1112) are
able to reproduce some of TSP-1-mediated biological eﬀects
in in vitro models (Rath et al., 2006a; Maxhimer et al.,
2009). However, 4N1 should no longer be considered as a
CD47-speciﬁc targeting agent as several studies pointed out
15 years ago its ability to induce cellular responses in a
CD47-independent fashion (Tulasne et al., 2001; Barazi et al.,
2002). In addition, there is a dearth of convincing in vivo
data concerning these peptides, probably due to moderate
aﬃnity to CD47 and poor pharmacokinetic properties, thus
requiring high dose treatments. Indeed repeated administrations
of an extended version of the 4N1 peptide named 4N1K (K-
1016RFYVVMWK1024-K) induce only modest changes in tumor
growth (Kalas et al., 2013), while 4N1K exhibits low stability
in plasma. Consideration of 4N1K as a CD47 agonist is all
the more controversial as its VVM motif is actually buried
within a hydrophobic β-strand arrangement of C-terminal TSP-
1, therefore, avoiding accessibility to CD47 without signiﬁcant
conformational changes (Kvansakul et al., 2004). However,
normal mode analysis and energy minimizations helped to
identify large amplitude motions of TSP-1 signature domain,
leading to opening of the hydrophobic cleft and allowing solvent
exposure of the 4N1 sequence (Floquet et al., 2008). Some studies
highlighted diﬀerences in 4N1K-induced responses between
CD47+/+ and CD47−/− cells or considering CD47 blocking
mAbs (Fujimoto et al., 2003; McDonald et al., 2004), which
remains unexplained in view of the above-mentioned studies
demonstrating 4N1 non-speciﬁcity. Despite these considerations,
others have suggested that some of the in vitro eﬀects of
4N1K are likely to be due to its hyper-adhesive nature rather
than its interaction with CD47, particularly as CD47-deﬁcient
cells are able to bind immobilized 4N1K (Leclair and Lim,
2014). Interestingly, a recently identiﬁed serum-stable analog
of 4N1K named PKHB1, in which natural L-amino acids
are replaced by their D counterparts, was demonstrated to
induce a twofold reduction in human chronic lymphocytic
leukemia xenografts growth (Martinez-Torres et al., 2015).
Nevertheless, caution should be observed about such TSP-
1-derived CD47 agonists as they might also induce adverse
inhibitory eﬀects on host DCs immunity (Weng et al.,
2014).
Among TSP-1 multiple domains, the main antiangiogenic
sequences are thought to reside within the type 1 repeats involved
in CD36 binding (Belotti et al., 2011). Indeed recombinant
3TSR fragments potently inhibit tumor growth in both syngeneic
melanoma and orthotopic human pancreatic carcinoma models
(Miao et al., 2001; Zhang et al., 2005). Subsequently, TSP-1-
derived peptidomimetics were developed and even reached phase
2 clinical trials. ABT-526 (Abbott Laboratories) was the ﬁrst
to be described as a modiﬁed peptide based on the GVITRIR
sequence of the second TSP-1 type 1 repeats (Haviv et al.,
2005), and yield impressive disease regression without any
signiﬁcant adverse eﬀects in tumor-bearing dogs (Rusk et al.,
2006). Thereafter a more soluble enantiomer with better PK/PD
proﬁle, named ABT-510, entered clinical trials. After showing
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relevant PK properties in phase 1 trials (Hoekstra et al., 2005;
Gietema et al., 2006), ABT-510 failed to give clear evidence
of eﬃcacy in phase 2 and led to severe adverse events such
as thrombosis and pulmonary embolism (Ebbinghaus et al.,
2007; Baker et al., 2008). ABT-510 is consequently no longer
tested in clinical development, however, a second-generation
mimetic named ABT-898 has recently emerged with improved
therapeutic activity in dogs with soft tissue sarcoma (Sahora
et al., 2012). While ABT-898 treatment eﬃciently allowed the
regression of established ovarian tumors in mice (Campbell
et al., 2011), it has not entered human development so far.
Conjointly, CVX-22 and CVX-045 (Pﬁzer) were developed fusing
TSP-1-derived peptidomimetics with a proprietary scaﬀold
antibody (Levin et al., 2007; Coronella et al., 2009). While
CVX-045 showed eﬃcacy in tumor xenografts by reducing
MVD and increasing necrotic cores (Li et al., 2011), only
limited beneﬁts were observed during phase 1 clinical trials
in association with severe adverse events (Molckovsky and
Siu, 2008), which probably explains why such “peptibodies”
have been discontinued from Pﬁzer pipeline in 2014 (Rader,
2014).
Original Strategies and Current
Developments
Aside from peptidomimetics based on sequences from the type
1 repeats, sm27 is a non-peptide small molecule mimicking
the FGF-2 binding site located in the type 3 repeats of TSP-
1 (Taraboletti et al., 2010) that exhibits in vitro and ex vivo
antiangiogenic properties (Colombo et al., 2010). Since 2010,
several computational studies have been conducted aiming to
optimize sm27:FGF-2 binding dynamics (Pagano et al., 2012;
Meli et al., 2014), and newly designed derivatives will presumably
be evaluated in vivo in future experiments. More recently,
we characterized a cyclic peptide derived from CD47, named
TAX2, that directly binds TSP-1 to antagonize TSP-1:CD47
interaction (Jeanne et al., 2015). TAX2 administration led to
a decrease in viable tumor volume in melanoma allograft
and potently inhibited pancreatic carcinoma xenograft growth,
together with a disruption of tumor-associated vascular network.
In vitro studies using CD36 blocking mAbs indicated that
the unpredicted antiangiogenic properties of TAX2 are likely
to be mediated by CD36 activation. According to the TAX2
proposed mechanism of action, such peptide may induce a
TSP-1 binding switch from CD47 to CD36. Appropriately,
TAX2 antitumor eﬀects are consistent with those observed
using TSP-1 recombinant fragments targeting CD36 in similar
experimental models (Miao et al., 2001; Zhang et al., 2005).
The use of recombinant 3TSR as a CD36-activating treatment
recently showed promising results in preclinical models of
glioblastoma and ovarian carcinoma (Choi et al., 2015; Russell
et al., 2015), therefore it seems relevant to assess the therapeutic
potential of TAX2 in the context of such pathologies. In
addition, ABT-898 was shown to be especially potent in the
female reproductive tract (Campbell et al., 2011), and CD47
was early considered as an ovarian tumor marker (Campbell
et al., 1992). Through its original mechanism of action which
supposes concomitant disruption of TSP-1:CD47 interaction and
enhancement of CD36 activation by TSP-1, TAX2 may inhibit
tumor progression while limiting many of the undesired side
eﬀects of broadly inhibiting important physiological functions
of CD47. Indeed, as TAX2 was designed to target TSP-1
speciﬁcally at the CD47 binding site, both TSP-1 and CD47
are presumed to remain free to interact with their respective
alternative ligands. Nevertheless, some putative side-eﬀects of
using TAX2 as an anti-cancer agent still need to be explored,
particularly as TSP-1 interaction with CD47 and/or CD36 is
also known to modulate platelet aggregation (Isenberg et al.,
2008d). While ABT-510 lack of eﬃcacy in clinical trials is
likely due to its inability to mimic the activity of full-length
TSP-1 (Ebbinghaus et al., 2007; Markovic et al., 2007), we
are convinced that original strategies, viz. the use of TAX2
or the identiﬁcation of new inhibitors that would target
pathway leading to TSP-1 repression, may provide realistic
treatment alternatives by ﬁnely controlling full-length protein
signaling. Interestingly, TAX2 was shown to inhibit endothelial
cell cGMP production under NO stimulation. According to
our assumptions, TAX2 may target the NO/cGMP pathway
downstream from eNOS through stimulation of TSP-1:CD36
interaction. Hence, unlike bevacizumab or other VEGF-targeting
blockbuster drugs, TAX2 may also inhibit downstream signals
resulting from angiogenic signals other than VEGF such as NO
production by stromal cells (Roberts et al., 2007). Currently,
further work is being done to improve TAX2 translational
potential.
Other molecules were also shown to cause an overall
anticancer response by involving the action of TSP-1.
Indeed trabectedin (ET-743, Yondelis), a marine natural
product approved as a second-line treatment of recurrent
ovarian cancer (Monk et al., 2012), exhibits antiangiogenic
activities by upregulating tumor cell expression of TSP-
1 (Dossi et al., 2015). Besides, a ﬁve-amino acid peptide
derived from prosaposin (DWLPK) was recently shown to
inhibit lung metastatic colonization through upregulation
of TSP-1 in Gr1+ myeloid cells (Catena et al., 2013).
Therefore, direct stimulation of TSP-1 or even strategies
that indirectly increase bioavailable TSP-1 within the pulmonary
microenvironment could therefore represent a relevant
translational antimetastatic approach. However, attenuation
of NO and activated CD47 corroborate with pulmonary
hypertension (Xu et al., 2004; Bauer et al., 2012) while TSP-
1 is a characteristic component of coronary atherosclerotic
plaques (Riessen et al., 1998). Therefore, inducing TSP-1
may lead to cardiovascular complications, especially in the
lung (Rogers et al., 2014). In addition, caution should be
exercised in generalizing the beneﬁts in other host organs,
as they might be dependent on the cytokine environment.
Particularly, Lee and collaborators reported that ADAMTS1-
mediated processing of TSP1 into antiangiogenic fragments
occurs diﬀerently for liver and lung metastases (Lee et al.,
2010).
Besides the above-described TSP-1-related therapeutic
strategies, much has also been done to propose alternative
methods to target CD47/SIRPα signaling. While current
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approaches have principally targeted the ubiquitously expressed
CD47, thus inevitably leading to oﬀ-target eﬀects, a novel
engineering development has recently emerged aiming to
target SIRPα speciﬁcally. The so-called “Velcro-CD47” (N3612)
consists of a high aﬃnity variant of the human CD47 extracellular
domain extended at the N-terminus with a short three amino-
acid peptide in order to increase binding aﬃnity to SIRPα
(Ho et al., 2015). Velcro-CD47 already proved its ability to
enhance macrophage phagocytosis of tumor cells in vitro and to
target the monocyte subpopulation speciﬁcally, and its putative
anticancer eﬃcacy will be further evaluated in pre-clinical
models.
Future Directions
In order to reach an optimal control of tumor progression,
future directions will aim to associate innovative approaches
targeting TSP-1/CD47 and TSP-1/CD36 signaling with existing
anticancer treatments. Indeed morpholino suppression of
CD47 expression was shown to markedly increase radiation-
induced delay in tumor growth considering two syngeneic
models of melanoma and squamous cell carcinoma (Maxhimer
et al., 2009; Ridnour et al., 2015). While it sensitizes the
tumor to ionizing radiation, CD47 deﬁciency concomitantly
confers radioprotection to normal tissues through activation of
autophagy (Soto-Pantoja et al., 2012b). This may be of particular
interest in the ﬁeld of blood cancer treatment with the aim
of minimizing the adverse eﬀects of total body irradiation,
especially as morpholino-induced CD47 gene silencing was
demonstrated to preserve circulating peripheral blood cells and
to protect gastrointestinal tissue from ionizing radiation (Soto-
Pantoja et al., 2013a). Therefore, future studies will determine
the appropriate strategies targeting CD47 with the purpose
of radiomitigation, with the potential of being translated into
clinical practice.
CD36-activating 3TSR treatment eﬃcacy was also evaluated
on top of conventional chemotherapy. While intermittent bursts
of MTD chemotherapy are currently considered in the treatment
of ovarian cancer, combination with 3TSR may facilitate the
uptake of drugs delivered at low-dose MET scheduling in
order to reach higher tumor regression rates in patients with
advanced EOC (Russell et al., 2015). Indeed combination of 3TSR
with carboplatin and paclitaxel MET chemotherapy considerably
promotes survival in a syngeneic murine model of EOC.
Interestingly, 3TSR is more eﬀective than ABT-598 in this
model, thus supporting the concept that the full function of the
type 1 repeats cannot be mimicked by a single short peptide
(Campbell et al., 2011). Another promising strategy consists
of combining the antiangiogenic property of 3TSR with the
pro-apoptotic TRAIL in order to target both tumor and tumor-
associated vessels (Ren et al., 2009). Such 3TSR/TRAIL fusion
protein was recently demonstrated to improve survival of mice
bearing intracranial human glioblastoma xenografts, therefore,
suggesting a potent translational potential of 3TSR/TRAIL
therapies into clinics (Choi et al., 2015).
Finally, TSP-1 peptidomimetics may be considered not only
for their direct therapeutic use, but also to enhance the
therapeutic delivery of cytotoxic drugs. Notably, a D-reverse
peptide derived from the native KRFKQDGGWSHWSPWSSC
motif within the TSR of TSP-1 was ﬁrst demonstrated to
inhibit breast tumor growth in a mouse xenograft model (Guo
et al., 1997). More recently, an aspartimide analog based on
the same TSP-1 sequence was shown to potentiate the activity
of doxorubicin in colon carcinoma xenografts. Indeed, such
a peptide is able to support the adhesion of doxorubicin-
containing liposomes to both tumor cells and endothelial cells,
thus leading to increased antiproliferative and antiangiogenic
activities (Rivera-Fillat et al., 2010).
CONCLUSION
To date, mAbs targeting CD47 are the best advance toward
clinical development and much interest is accorded to massive
anti-CD47 blocking strategies, even within non-scientiﬁc
skilled communities. Accordingly, a growing number of almost
sensational reports excessively praise the therapeutic potential
of CD47-targeting anticancer immunotherapies on social
networks, video sharing platforms or popular-science writings
(Williams, 2012; Foley, 2013), probably with a promotional
and fund raising purpose. Noteworthy work of Weissman and
collaborators in immunodeﬁcient mice has proved preclinical
eﬃcacy of anti-CD47 mAbs in a wide range of xenograft models
including leukemia (Chao et al., 2011a), lymphoma (Chao
et al., 2011b), multiple myeloma (Kim et al., 2012), and several
solid tumors (Edris et al., 2012; Willingham et al., 2012a).
However, we are deeply convinced that genetic ablation or
antibody blockade of CD47 may not represent a fully satisfying
anticancer therapeutic alternative due to adverse eﬀects and/or
concomitant attenuation of beneﬁcial functions, and that a
more nuanced picture could be exposed to cancer patients.
Indeed, massive extinction of any protein/receptor/signaling
pathway might lead to adverse eﬀects and resistance, while
more accurate strategies are needed to regain the baseline.
In particular, a global vision of the numerous molecular and
cellular actors involved should be adopted when considering
matricellular proteins and their receptors in anticancer drug
development. Anti-CD47 mAbs could oﬀer clear beneﬁts in
the treatment of cardiovascular diseases, however their use as
anticancer drugs is likely to encounter the same limitations
as bevacizumab, i.e., hypertension, thromboembolism,
and tumor recurrence (Gil-Gil et al., 2013). While genetic
modulation of CD47 expression could represent an alternative
to antibody-based strategies, further clinical development of
previously described morpholino-based approaches may require
repeated administrations of high doses, due to morpholino
oligonucleotides poor cell and tissue uptake as well as their
rapid renal clearance (Moulton and Moulton, 2010). Besides,
siRNA and miRNA-based strategies may provide viable
alternative to morpholino-based CD47 silencing (Wang et al.,
2015).
In our opinion, future research should focus on small
molecules that allow a ﬁner and more accurate regulation,
thus leading to adequate responses and limited adverse eﬀects.
Among the variety of innovative approaches, peptides represent a
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fast-growing class of new therapeutics (Diao and Meibohm,
2013) and many structural modiﬁcation strategies have been
developed recently to improve their performance as drugs
(Di, 2015). The combination of such cutting-edge strategies
with conventional anticancer agents will help optimize dosing
schedules, whose inﬂuence on resistance acquisition is often
under evaluated, particularly among anti-VEGF approaches
(Clarke and Hurwitz, 2013). Looking ahead, original and
selective TSP-1-related antireceptor strategies could improve
long-term beneﬁts by overcoming many undesired eﬀects. The
next challenges will concern the translation of these small
molecules into the clinic, as well as the identiﬁcation of
optimal combinatorial strategies with standard chemotherapy
and radiotherapy.
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